Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Retrovir Goes Generic

This article was originally published in The Pink Sheet Daily

Executive Summary

Zidovudine ANDAs from Ranbaxy, Roxane and Aurobindo are the first generic pediatric AIDS drugs approved for the U.S. market.

You may also be interested in...



Dingell May Tighten Inspection Provisions In Safety Bill, After Ranbaxy Alert

House Energy and Commerce Committee Chairman John Dingell, D-Mich., is likely to strengthen FDA mandates proposed in his evolving global drug safety bill, in light of the new Import Alert for more than three dozen Ranbaxy products

Dingell May Tighten Inspection Provisions In Safety Bill, After Ranbaxy Alert

House Energy and Commerce Committee Chairman John Dingell, D-Mich., is likely to strengthen FDA mandates proposed in his evolving global drug safety bill, in light of the new Import Alert for more than three dozen Ranbaxy products

Generic Retrovir Capsule Formulation Clears FDA

Approval of Aurobindo's zidovudine marks the first generic HIV/AIDS drug in capsule form in the U.S.

Related Content

Topics

UsernamePublicRestriction

Register

PS062914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel